Signals, Powered By EquityPandit
Panacea Biotec, has signed two long-term agreements with Serum Institute of India and its wholly owned subsidiary, Bilthovan Biologicals B.V (BBIO).
Under the agreement, Serum Institue is authorized to manufacture and sell fully liquid whole cell pertussis (wP) and salk based injectable polio vaccine (IPV) based Hexavalent vaccine (DTwPHepB-Hib-IPV) developed and commercialized by Panacea Biotec.
Serum Institute of India will make sure supply of IVP bulk to Panacea Biotec, from its wholly owned subsidiary, Bilthovan Biologicals B.V (BBIO).
